U.S. Markets open in 1 hr 36 mins

Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable

ALLISON GATLIN
Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable

A tiny biotech called Proteostasis won't be able to rival Vertex in cystic fibrosis treatment, analysts said Monday. Proteostasis' triple-medicine missed the bar set by Vertex's treatment.